Patent review of 5,000+ oral GLP-1 drug candidates reveals key structural features for future non-injectable diabetes therapy
Analysis of 67 patents (5,000+ compounds) reveals key SAR trends for danuglipron/lotiglipron-like oral GLP-1 agonists: carboxyl groups boost activity, bioisosteric replacements improve pharmacokinetics, and promising chemotypes suggest approved oral agents are achievable.
Quick Facts
What This Study Found
67 patents; 5,000+ compounds analyzed; 2021-2024. SAR: carboxyl groups → high activity; bioisosteres → better ADME; privileged fragments identified; heterocycle replacements viable; piperidine modifications promising. Clinical: danuglipron/lotiglipron had issues but spawned robust pipeline.
Key Numbers
How They Did This
Patent review of Espacenet and Google Patents databases (Jan 2021-Jul 2024). SAR analysis of danuglipron- and lotiglipron-like agonists. 67 publications, 5,000+ compounds.
Why This Research Matters
The injection barrier limits GLP-1 drug adoption. Identifying SAR trends from 5,000+ oral candidates accelerates the development of non-injectable alternatives that could reach billions more patients.
The Bigger Picture
The oral GLP-1 pipeline is enormous—5,000+ compounds in just 3 years. This suggests oral GLP-1 drugs are not a question of "if" but "which one" and "when," potentially transforming diabetes and obesity treatment worldwide.
What This Study Doesn't Tell Us
Patent review—not clinical data. Most compounds are untested in humans. Complex GLP-1R signaling may limit small-molecule approaches. Biased signaling implications unknown.
Questions This Raises
- ?Which oral GLP-1 candidate will reach approval first?
- ?Can small molecules achieve the same weight loss as injectable peptides?
- ?Will oral GLP-1 drugs be cheaper than injectable versions?
Trust & Context
- Key Stat:
- 5,000+ oral GLP-1 candidates Massive patent pipeline of danuglipron/lotiglipron-like oral small molecules with identified SAR trends suggests approved oral GLP-1 drugs are imminent
- Evidence Grade:
- Comprehensive patent SAR review. Chemical evidence, not clinical.
- Study Age:
- Published in 2025; patents 2021-2024.
- Original Title:
- "Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).
- Published In:
- Current medicinal chemistry (2025)
- Authors:
- Tolkacheva, Elena V, Saliev, Alexandr Yu, Salakhov, Tagir L, Balakin, Konstantin V, Ivanov, Roman A, Chernyshov, Vladimir V
- Database ID:
- RPEP-13818
Evidence Hierarchy
Frequently Asked Questions
Will there be a GLP-1 pill for weight loss?
Very likely. This review analyzed over 5,000 oral GLP-1 drug candidates from 67 patents. While Pfizer's first attempts (danuglipron, lotiglipron) had issues, the enormous number of new candidates suggests an approved oral GLP-1 drug is achievable within a few years.
How are oral GLP-1 drugs different from injectable ones?
Injectable GLP-1 drugs are peptides (small proteins) that must be injected because they would be destroyed by digestion. Oral small-molecule agonists are traditional drug-like chemicals that survive digestion and activate the same GLP-1 receptor. Over 5,000 such molecules are now in development.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13818APA
Tolkacheva, Elena V; Saliev, Alexandr Yu; Salakhov, Tagir L; Balakin, Konstantin V; Ivanov, Roman A; Chernyshov, Vladimir V. (2025). "Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).. Current medicinal chemistry. https://doi.org/10.2174/0109298673366258250710101146
MLA
Tolkacheva, Elena V, et al. ""Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).." Current medicinal chemistry, 2025. https://doi.org/10.2174/0109298673366258250710101146
RethinkPeptides
RethinkPeptides Research Database. ""Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Ago..." RPEP-13818. Retrieved from https://rethinkpeptides.com/research/tolkacheva-2025-nextinclass-glp1r-danuglipron-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.